Dr. Jonathan Sadeh, MD, MSc, Senior Vice President of Immunology and Fibrosis Development, Global Drug Development at Bristol Myers Squibb discusses the recent approval of SOTYKTU™ (deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action, for the treatment of patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. To learn more visit SOTYKTU.com
Jonathan serves as senior vice president of Immunology and Fibrosis Development at Bristol Myers Squibb. In this role, Jonathan leads a team that oversees the development of potential medicines for patients with immune-mediated and fibrotic diseases, where he applies knowledge and insights from years of experience in immunology and inflammation.
This includes development activities for assets pre-approval as well as approved medicines within the portfolio. Through the study of early, late-stage and approved assets, Jonathan and his team work to expand Bristol Myers Squibb’s franchise across a broad range of diseases in the areas of rheumatology, gastroenterology, dermatology and neurology, as well as fibrotic conditions like pulmonary fibrosis. Since joining Bristol Myers Squibb in 2019, he has been instrumental in shaping the company’s immunology strategy and ambition of creating an industry-leading franchise.
Jonathan previously held leadership roles at Sanofi, AstraZeneca and Schering-Plough (now a part of Merck), where he led teams and functions in both early and late development and was responsible for development and registration of drugs in the respiratory and rheumatology areas.
Before entering the pharmaceutical industry, he worked at Brigham and Women’s hospital in Boston as a physician scientist in the pulmonary division. He completed his pulmonary and critical care fellowship training at Massachusetts General Hospital and Brigham and Women’s hospitals, and received a master’s degree in clinical research from Harvard Medical School.